Search

Nie et al. show that myocardial CCDC25 detects doxorubicin-induced neutrophil extracellular trap DNA and activates reactive oxygen species production and autophagy, leading to cardiotoxicity. Targeting CCDC25 exerts a cardioprotective effect without impacting the antitumor activity of doxorubicin in lymphoma and breast cancer models.

Therapeutic options for patients with triple-negative breast cancer (TNBC) in later-line setting are limited. Here the authors report the results of a phase 2 clinical trial to evaluate efficacy and safety of the combination of camrelizumab (anti-PD1), apatinib (VEGFR2 inhibitor), and eribulin in patients with heavily pre-treated advanced TNBC.

Song and colleagues report that in breast cancer, chemotherapy induces the IRENA lncRNA, which reprograms tumor suppressive macrophages to protumorigenic phenotypes and promotes chemoresistance.

Effective control of tumors requires the presence of inflammatory helper and cytotoxic T cells. Song and colleagues demonstrate that the protein RGS1 cell-intrinsically regulates effector T cell homing to tumors and thereby impairs tumor control.

lncRNAs can regulate immune responses at a number of levels. Song and colleagues demonstrate that the lncRNA NKILA is expressed by tumor-associated cytotoxic T cells, and this predisposes them to activation-induced cell death and escape of tumors from immunologically mediated destruction.

It is known that genotoxic stress induces high levels of ROS and deplete cellular glutathione stores. Here, Cao et al. uncover a β-catenin-dependent TCF/LEF-independent mechanism that promotes histone-mediated transcriptional activation of glutathione synthesis.

Here the authors show that, when phosphorylated at Tyr34, THEMIS behaves as an allosteric activator to phosphatase SHP1, ensuring appropriate negative regulation of T cell antigen receptor signaling and thus assisting in T cell maturation and expansion.

The tumour-specific circular RNA FAM53B is highly immunogenic and can induce anti-tumour responses in mouse models of breast cancer and melanoma, expanding the repertoire of anticancer targets for development.

Cyclin D1 is involved in tamoxifen resistance in breast cancer (BC) but how it is regulated is unclear. Here, the authors demonstrate that the LncRNA DILA1 contributes to tamoxifen resistance in breast cancer by binding to Cyclin D1 and preventing its degradation.

Altered lipid metabolism has been associated with tumour malignancy, but underlying mechanisms are not clear. Here the authors show that proto-oncogene Src interacts and phosphorylates metabolic enzyme phosphatidic acid phosphatase LPIN1 (lipin-1) to promote growth and metastasis in breast cancer.

While aromatase inhibitors (AI) are an effective treatment for patients with estrogen receptor positive breast cancer, resistance presents a major obstacle. Here, the authors identify DIO3OS, a long noncoding RNA, as a driver of AI-resistance in breast cancer through the enhancement of aerobic glycolysis.

HIF1alpha is reported to drive tumourigenesis through activating glycolysis. Here, the authors show that HIFAL, the HIF1alpha antisense long non-coding RNA, and HIF1alpha form a positive feed-forward loop which is essential for HIF1a-mediated metabolic reprogramming and oncogenic role.

DNA from neutrophil extracellular traps interacts with the transmembrane receptor CCDC25 on cancer cells, activating the ILK-β-parvin pathway to enhance cell motility and promote distant metastases.

Chen et al. show that tumour-associated macrophages transmit HIF-1α-stabilizing long noncoding RNA through extracellular vesicles to breast cancer cells, thereby enhancing tumour glycolysis and chemoresistance.

Acquired resistance to chemotherapy can lead to multi-drug resistance and poor prognosis in cancer. Here, the authors show that Rac1 increases glycolysis and non-oxidative pentose phosphate pathway activity leading to neoadjuvant chemotherapy (NAC) resistance, thus its inhibition sensitizes resistant breast cancer PDXs to NAC.

Most breast cancer patients are estrogen receptor positive and thus benefit from treatments that inhibit estrogen production; however, one third of tamoxifen-treated patients develops resistance and relapse. Here the authors show that tamoxifen resistant cells are resistant to chemotherapy because of BARD1 and BRCA1 upregulation.

Chemoresistance and metastasis are tightly associated features in non-small cell lung cancer (NSCLC). Here, the authors show that resistant NSCLCs have high levels of miR-128-3p which promotes EMT and cancer stem cell survival through the modulation of both Wnt/B-catenin and TGF-β pathway.

BRMS1, a component of the Sin3A–HDAC repressor complex, blocks invasion and migration of breast cancer cells. Here the authors show that BRMS1-like (BRMS1L) inhibits breast cancer metastasis by blocking epithelial to mesenchymal transition through transcriptional suppression of the FZD10 receptor for Wnt ligands.

Fibroblast activity is regulated by tissue macrophages. Here the authors show that two miRNAs regulated by IL-4 and IL-13 in macrophages target SOCS1 and PPARγ and modulate profibrogenic macrophage program in vitro and in vivo, and that alterations of these miRNAs are found in fibrosis.

We introduce a major scientific endeavour called π-HuB (proteomic navigator of the human body), its aim being to generate and harness multimodality proteomic datasets to enhance our understanding of human biology.

Resistance to therapy is a significant issue for patients with metastatic breast cancer (MBC). Here the authors analyze total miRNA from serum samples of 386 MBC patients before treatment with a follow up of 31 months and define a four miRNA signature that predicts the therapeutic benefit of trastuzumab.

Cai et al. show that CK1α suppresses lung cancer growth by inducing autophagy through a PTEN–AKT–FOXO3a pathway that ultimately leads to ATG7 expression.

Immune checkpoint blocking therapies do not always work and come with some risks, but identifying non-responders and patients at risk of adverse events is becoming easier and more accurate.

Cancer-associated fibroblasts (CAFs) are often the most abundant cell type in the tumour microenvironment. Here, Song and colleagues discuss how to target or harness these cells for cancer therapy. They highlight the progress made to date and the remaining challenges in bringing CAF-targeted therapies to the clinic.